What is a suitable second choice for progestogen in hormone replacement therapy if Prometrium (progesterone) is not covered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Second-Line Progestogen Options When Prometrium Is Not Covered

If Prometrium (micronized progesterone) is not covered, medroxyprogesterone acetate (MPA) 10 mg daily for 12-14 days monthly (sequential) or 2.5-5 mg daily (continuous) is the most widely available and evidence-based alternative, though norethindrone acetate 1 mg daily offers a superior cardiovascular and metabolic profile. 1, 2

Primary Alternative: Medroxyprogesterone Acetate (MPA)

MPA remains the most commonly prescribed alternative due to extensive safety data and widespread availability, despite its less favorable metabolic profile compared to natural progesterone. 1

Dosing Regimens:

  • Sequential regimen: MPA 10 mg daily for 12-14 days every 28 days when using transdermal 17β-estradiol patches (50-100 μg daily) 2
  • Continuous regimen: MPA 2.5-5 mg daily provides full endometrial protection long-term and prevents withdrawal bleeding 2, 3

Important Caveats:

  • MPA has documented adverse effects on lipid profiles, vasomotion, and carbohydrate metabolism compared to natural progesterone 1
  • The continuous combined regimen is superior to sequential for long-term endometrial protection 2, 4
  • MPA may obscure the cardioprotective effects of estrogen 4

Preferred Alternative: Norethindrone Acetate

Norethindrone acetate 1 mg daily offers better metabolic and cardiovascular outcomes than MPA while maintaining excellent endometrial protection. 1, 5

Key Advantages:

  • Lower doses (1 mg) are as effective as higher doses (5 mg) for endometrial protection with minimal lipid changes 6
  • Superior bleeding control and endometrial protection compared to other progestogens 5
  • Positive effects on bone metabolism, increasing bone mass more than expected 5
  • Does not negatively influence serum lipids when given in correct dosage 5

Practical Considerations:

  • Use 1 mg daily in continuous combined regimens to minimize androgenic effects 6
  • The 12-14 day duration in sequential regimens is critical for adequate endometrial protection 2, 6

Third-Line Option: Dydrogesterone

Dydrogesterone is listed among ESHRE-recommended progestogens, though evidence in premature ovarian insufficiency populations is limited. 1

  • Enhanced oral bioavailability compared to natural progesterone 1
  • Lacks robust endometrial safety data in POI populations 1

Alternative Delivery System: Levonorgestrel IUS

The levonorgestrel intrauterine system provides reliable endometrial protection with fewer systemic adverse effects than oral routes. 2

  • Delivers progestogen directly to the uterus 2
  • Recommended by the British Menopause Society as an alternative delivery method 2
  • Particularly useful for patients experiencing systemic progestogen side effects

Critical Safety Monitoring

Perform baseline endometrial ultrasound to document endometrial thickness before initiating any progestogen regimen. 2

  • Consider annual endometrial thickness monitoring, especially with off-label regimens 2
  • Sequential regimens require at least 12-14 days of progestogen monthly to prevent endometrial hyperplasia 2, 6
  • Continuous combined regimens provide superior long-term endometrial protection compared to sequential 2, 4

Common Pitfalls to Avoid

  • Never use sequential progestogen for fewer than 12 days monthly—this provides insufficient endometrial protection 2, 6
  • Avoid high-dose MPA when lower-dose norethindrone acetate (1 mg) can achieve the same endometrial protection with better metabolic effects 6
  • Do not assume all progestogens have equivalent cardiovascular safety profiles—natural progesterone and lower-dose norethindrone acetate are preferable to MPA 1, 4
  • Be cautious with norethindrone in patients with thromboembolism history, uncontrolled hypertension, or cardiovascular disease 7, 8

Related Questions

In a 57-year-old woman with low estradiol (<5 pg/mL) and progesterone (0.3 ng/mL) while taking medroxyprogesterone acetate 5 mg daily and a transdermal estradiol patch delivering 0.05 mg/24 h applied twice weekly, how should the estradiol regimen be adjusted to achieve appropriate post‑menopausal replacement levels?
What to do for amenorrhea in a patient on Noriday (Norethisterone)?
In a 47-year-old woman with early menopause, osteopenia, and a stable BIRADS 3 breast lesion, who is using a 0.1 mg/day transdermal estradiol patch and nightly 300 mg progesterone, has a low serum estradiol (<23 pg/mL) and symptoms of irritability, brain fog, and occasional hot flashes, should her hormone replacement therapy be adjusted?
In a patient on hormone replacement therapy with estradiol 0.1 mg transdermal patch twice weekly and a levonorgestrel‑releasing intrauterine device (Marina IUD), does adding oral micronized progesterone 100 mg provide any overall benefit beyond possible improvement in sleep or anxiety?
In a 50‑year‑old woman on combined HRT with transdermal estradiol patch (Estradot 25 µg/24 h) and oral micronized progesterone (Utrogestan 100 mg daily) who still has brain fog and insomnia, no vaginal bleeding, and requests an earlier refill, should the estradiol dose be increased to a higher‑strength patch rather than refilling the same dose?
What does a scalloped hemidiaphragm (half of the diaphragm) on an X-ray (X-ray computed tomography) indicate?
Is propranolol (beta blocker) effective for treating panic attacks?
What is the appropriate management for a patient with leukopenia, eosinophilia, lymphocytopenia, neutropenia, and thrombocytopenia?
Do narcissists use verbal abuse, such as name-calling and yelling, to control their spouses?
How should a patient with iron deficiency anemia and macrocytic anemia be treated?
What are the next steps for a patient with a Prostate Specific Antigen (PSA) level of 3.00 ng/mL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.